In this exclusive video interview, pharmaphorum’s editor-in-chief Jonah Comstock sits down with Carlos Buesa, CEO of Oryzon ...

Meanwhile, the FDA has asked manufacturers of flu vaccines to update their labels to include warnings about the risk of ...

For the US, it means that the UK will spend more on medicines and offer more support to industry. Over the next ten years, ...

Illumina has unveiled a database of genomic alterations, called the Billion Cell Atlas, that can be used to identify and ...

Hippocratic AI has expanded its focus with the acquisition of Grove AI, a specialist in AI used in pharma R&D, to complement ...

In our final batch of Changing Faces columns for 2025, we’re detailing a flurry of senior leadership appointments in recent ...

Former Moderna executive Dr Melanie Ivarsson has been appointed chief executive of the UK's Health Data Research Service ...

Novo Nordisk's new chief executive, Mike Doustdar, has told the JPM Healthcare conference that the key to competing in the GLP-1 agonist category for weight loss will be to make the most of cash-pay ...

The current state of radiotherapeutics is “the isotope wars”, according to Jack Hoppin, CEO of Boston’s Ratio Therapeutics.

As the biopharma industry heads into 2026, insights gained over the past year are set to be applied and scaled, especially in ...

Anthropic has launched Claude for Healthcare, a suite of AI tools for health systems, payers, and patients, in the latest ...